Unicycive Therapeutics (UNCY) Change in Accured Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Change in Accured Expenses data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 188.87% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$1.0 million (down 233.2% YoY), and the FY2025 full-year result was -$2.5 million, down 417.09% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $2.3 million, up from -$1.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.3 million in Q1 2026 and bottomed at -$2.3 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $24000.0 (2022), against an average of $183117.6.
• The widest annual swing landed in 2023, when Change in Accured Expenses sank 904.17%; it then jumped 525.91% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$641000.0 in 2022, then surged by 166.61% to $427000.0 in 2023, then surged by 127.4% to $971000.0 in 2024, then tumbled by 286.82% to -$1.8 million in 2025, then jumped by 225.96% to $2.3 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.3 million (Q1 2026), -$1.8 million (Q4 2025), and $775000.0 (Q3 2025), per Business Quant data.

Peer Comparison